purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation purpose make world smarter happier richer founded motley fool financial service company dedicated making world smarter happier richer motley fool reach million people every month premium investing solution free guidance market analysis foolcom toprated podcasts nonprofit motley fool foundation orgo earnings call period ending december image source motley fool organogenesis orgo q earnings callfeb pm etcontents prepared remark question answer call participant prepared remark operatorwelcome lady gentleman fourth quarter fiscal year earnings conference call organogenesis holding inc time participant placed listenonly mode please note conference call recorded recording available company website replay shortly begin would like remind everyone remark today may contain forwardlooking statement based current expectation management involve inherent risk uncertainty could cause actual result differ materially indicated including risk uncertainty described company filing security exchange commission including item excuse including item risk factor company recent annual report sequential filing quarterly report cautioned place undue reliance upon forwardlooking statement speak date made although may voluntarily time time company undertakes commitment update revise forwardlooking statement whether result new information future event otherwise except required applicable security law call also includes reference certain financial measure calculated accordance generally accepted accounting principle gaap generally refer nongaap financial measure reconciliation nongaap financial measure comparable measure calculated presented accordance gaap available earnings press release investor relation portion website would like turn call mr gary gillheeney sr organogenesis holding president chief executive officer chair board please go ahead sirgary gillheeney president chief executive officer thank operator welcome everyone organogenesis holding fourth quarter fiscal year earnings conference call joined call today dave francisco chief financial officer let start brief agenda cover prepared remark begin overview fourthquarter revenue result update key operating strategic development recent month dave provide indepth review fourthquarter financial result balance sheet financial condition yearend well financial guidance introduced press release afternoon share closing thought open call question sale result came low end guidance range outlined thirdquarter conference call reflect expected challenging operating environment result local coverage determination announced subsequently withdrawn last fall specifically fourthquarter guidance range assumed continued significant business disruption driven customer confusion uncertainty outlined last quarter earnings call expected sale rep spending time servicing existing customer regaining lost customer versus cultivating new customer adoption thus impacting yearoveryear growth trend quarter additionally higher end guidance range assumed improvement operating environment move q ultimately materialize despite challenging quarter pleased see positive momentum business trend experienced toward end december continue early commercial team continues see progress broadbased effort reengage customer bring product back healing algorithm formulary encouraged evidence commercial support program implemented enhance existing customer relationship regain lost account proving effective importantly dedicated majority time share voice fourth quarter toward clarifying misinformation market refocused commercial resource drive growth customer base emphasizing differentiated product clinical value turning update operational progress recent month ongoing phase clinical trial evaluating use renu management symptom associated knee osteoarthritis continue progress planned reminder renu unique cryopreserved amniotic suspension allograft asa containing viable cell extracellular matrix importantly rich antiinflammatory regenerative growth factor achieved last patient last visit milestone january first phase clinical trial evaluate efficacy renu treatment symptomatic knee osteoarthritis preparation database lock analysis currently underway currently targeting completion topline data analysis end april intend share publicly via press release renu received fda regenerative medicine advanced therapy rmat designation osteoarthritis knee underscore strength existing clinical evidence potential address largely unmet medical need previously discussed expect subsequent discussion fda regarding clinical data requirement bla intend propose first phase clinical trial combined published patient rct valid scientific evidence sufficient bla approval also pleased progress seeing second phase clinical trial renu clinical site running enrolled patient date difficult predict pace enrollment precision current timeline u achieving full enrollment first quarter ahead original expectation started enrollment second phase clinical trial last september additionally consistent first phase clinical trial track enroll severe knee oa patient population also known kls known treatment completely cure knee oa possible treat disease symptom goal avoiding delaying costly invasive knee replacement surgery successful renu would fdaapproved biologic intraocular injection improve symptom severe case oa let turn dave dave dave francisco chief financial officer thanks gary begin review fourthquarter financial result unless otherwise specified growth rate referenced prepared remark yearoveryear basis net revenue fourth quarter million advance wound care net revenue fourth quarter million also net revenue surgical sport medicine product fourth quarter million gross profit fourth quarter million net revenue compared last year decrease gross profit margin resulted primarily shift product mix compared prior year period decrease pricing certain product operating expense fourth quarter million compared million last year decrease million decrease operating expense fourth quarter driven million decrease selling general administrative expense offset partially million increase research development cost compared prioryear period fourthquarter gaap operating expense included million restructuringrelated charge compared million prior year well million compensation expense related retention sale employee impacted lcd compared cost fourth quarter excluding item noncash intangible amortization million period nongaap operating expense fourth quarter decreased million year year material reduction nongaap gaap operating expense reflects proactive strategy manage cost light challenging operating environment made difficult strategic decision mitigate impact profitability lower fourthquarter revenue result operating loss fourth quarter million compared operating income million last year decrease million net loss fourth quarter million compared net income million last year decrease million adjusted net income fourth quarter million compared million last year decrease million reminder adjusted net income defined gaap net income adjusted exclude effect amortization restructuring charge certain item including compensation expense related retention sale employee impacted lcd resulting income tax item adjusted ebitda fourth quarter million net revenue compared million net revenue last year believe proactive effort optimize cost structure key contributor ability deliver positive adjusted net income adjusted ebitda exceeded low end guidance range q provided full reconciliation adjusted net income adjusted ebitda result earnings release turning brief review financial result month ended december st net revenue million compared million year ended december st decrease million approximately yearoveryear decline occurred fourth quarter decrease net revenue driven decrease million net revenue advanced wound care product decrease million net revenue surgical sport medicine product adjusted ebitda million net revenue compared adjusted ebitda million net revenue year ended december st decrease million occurred fourth quarter turning balance sheet december st company million cash cash equivalent restricted cash million debt obligation compared million cash cash equivalent restricted cash million debt obligation december st also million available borrowing revolving credit facility december st turning review financial guidance introduced press release afternoon month ending december st company expects net revenue million million representing yearoveryear increase range compared net revenue million year ended december st net revenue guidance range assumes net revenue advanced wound care product million million representing yearoveryear increase range net revenue surgical sport medicine product million million representing yearoveryear increase range term profitability guidance company expects generate gaap net income loss range million net loss net income million adjusted net income loss range million adjusted net loss adjusted net income million also expect ebitda range million million adjusted ebitda range million million addition formal financial guidance providing consideration modeling purpose reminder first half exceeded expectation strong business momentum continued early part third quarter ahead final lcd announcement early august result expectation growth skewed toward back half given comparable quarterly growth rate modeling purpose expect firstquarter revenue range approximately million million profitability guidance assumes gross margin approximately gaap operating expense increase approximately year year total nongaap operating expense increase approximately year year nongaap operating expense exclude noncash intangible amortization approximately million note expected increase operating expense year primarily related incremental investment clinical study regulatoryrelated spending preparation renewed bla effort fullyear operating expense also reflects strategic investment support key commercial initiative finally fullyear profitability guidance range also assume total interest expense approximately million million gaap tax rate range negative low end range positive high end range continue assume nongaap tax rate adjustment noncash depreciation approximately million noncash stock comp expense approximately million capex million weighted average diluted share count approximately million turn call back gary closing remarksgary gillheeney president chief executive officer thank dave open call question wanted share additional thought outlook underlying assumption supporting guidance environment remains challenging pleased see business trend show improvement early commercial team continues see progress effort reengage customer encouraged evidence commercial support program implemented enhance existing customer relationship regain lost account proving effective proud team continued commitment mission guidance reflects return revenue growth fueled new product launch across advanced homecare surgical sport medicine market including contribution new license agreement vivex biologics view license agreement great example effort identify growth marginaccretive highreturn opportunity leverage valuable commercial infrastructure leading market position advance wound care adding new product commercial team solution offering expect enhance share voice providing value customer broadening broadening portfolio differentiated treatment solution financial guidance also reflects intention continue invest strategically business support key longterm growth initiative including renewed clinical regulatory strategy believe represents significant value driver future importantly despite increased investment expect deliver solid adjusted ebitda operating cash flow help u continue enhance balance sheet financial condition remain confident longterm opportunity organogenesis expect remain leader space highly innovative efficacious product deliver mission provide integrative healing solution substantially improve outcome lowering overall cost care turn call operator open call question thank question answer operatorthank sir operator instruction first question today coming ryan zimmerman btig line openryan zimmerman btig analyst good afternoon thanks taking question guy hear okgary gillheeney president chief executive officer ryan good afternoonryan zimmerman btig analyst right great thank guy color appreciate certainly early commentary first quarter guess gary know would helpful get thought recovery market know kind mean context sound like business trend improved december know reconciling first quarter guidance still kind contemplating recovery business given guidance sharing street first quartergary gillheeney president chief executive officer sure see improvement end december actually seen improvement october kind flattened experienced turnover fourth quarter affected november december last two week really started see improvement january typically know seasonally period flat trend really started move positively february result retention effort account people well know national sale meeting end january know relaunched strategy effective sale since national sale meeting really strong encouraged encouraged account bringing back productivity rep action took fourth quarter streamline improved productivity commercial operation starting take effect producing result think know thing continue get better second half quarterryan zimmerman btig analyst okdave francisco chief financial officer ryan thing would add recognize first quarter quite strong growth comp issue wellryan zimmerman btig analyst yeah thank pointing dave helpfuldave francisco chief financial officer sureryan zimmerman btig analyst kind dovetail question mean look adjusted ebitda guidance know stepping back little bit year also reflective maybe program putting place past quarter know would love get philosophy kind know thinking managing profitability year maybe know think taking foot gas little bit know bolster spend drive growth drive new product know would like understand thought also think margin cadence dave know look gross margin fourth quarter know materially third quarter know quickly bounce back view context guide think gave today thanks taking questionsdave francisco chief financial officer yeah sure overall spend would say one piece fairly material step rd know pretty exciting time inflection point within renu program obviously know inevitable would start kick time know several thing happening perspective second trial moving enrolling quite well gary mentioned got expense associated obviously preparation go know making sure ready submit bla quite bit work going think think back last time guided issued guidance fourth quarter back q time would anticipated operating expense nongaap operating expense guided q expected flat took several cost action came minus two building back infrastructure return growth yeah conscious profitability think given decline saw tried best manage bottom line well think continue key strategic investment keep making keep moving forward asked specifically gross margin think start return normal cadence migrate know throughout year volume come know talked recently know seeing seeing pressure price standpoint big piece q around mix higher contribution margin product specifically impacted quite significantly lcd know expect dig way go q mean excuse ryan zimmerman btig analyst ok well could sneak one know kind ultimate question investor asking resumption view guidance lcd return know gary would appreciate view potential occur factoring estimate gary gillheeney president chief executive officer sure obviously know know whether change new lcd policy coming guess thinking probably anything significant certainly beginning year think physician fee schedule coming may dovetailing around might say think know election year physician fee schedule coming know amount issue last lcd think process robust transparent think physician fee schedule may impact designed think know see anything happening first half year second half year would expect anything significant know answer obviously considered considered impact lcd change guidanceryan zimmerman btig analyst understood thank taking questionsdave francisco chief financial officer course thanks briangary gillheeney president chief executive officer thank brianoperatorthank one moment next question next question coming ross osborn cantor fitzgerald line openross osborn cantor fitzgerald analyst hi guy thanks taking question maybe little bit fourth quarter would discus rep turnover look like lost maybe rep followup parse rep productivity versus hiring new rep reaching guidance rangedave francisco chief financial officer yeah mean obviously reported rep count frankly little bit misleading two category rep many company probably specialist associate kind see throughout year fourth quarter fairly significant dropoff associate know seeing best associate get promoted specialist role know specialist role know kind really maintained take look total amount associate specialist look like level productivity increase quite significantly look specialist standpoint one generating vast majority revenue minor uptick ross osborn cantor fitzgerald analyst ok perfect thank clarifying maybe one surgical sport realize much smaller piece business guidance range term growth quite large could maybe walk u driver hitting low high end thatdave francisco chief financial officer yeah sure mean think obviously fairly wide range percentage basis much smaller business continue ramp know know know kind repositioning mode time since fda upregulation renu nucel know really position drive growth view right leadership building direct rep broadening channel access know agency reach bringing new product market feel quite good opportunity set got front u know think going good year know see lot opportunity u going forward wellross osborn cantor fitzgerald analyst ok perfect last one u would walk u rationale license manufacturing agreement vivexdave francisco chief financial officer yeah sure mean opportunity u bring another product market dehydrated product dual layer commercialized right know standpoint think gary mentioned growth accretive gm accretive profit know ebitda accretive think real opportunity u continue identify opportunity really kind add bag leverage know broad commercial infrastructure leadership position advanced wound care great partnership excited look forward know continuing report progress make thereross osborn cantor fitzgerald analyst sound great thanks taking questionsdave francisco chief financial officer thanks rossgary gillheeney president chief executive officer thanks rossoperatorthank operator instruction next question coming drew ranieri morgan stanley line opendrew ranieri morgan stanley analyst hi gary david thanks taking question maybe touch something ryan brought first question thinking recapturing past account maybe walk u like actually seeing ground level clinician snap back business get back run rate immediately kind like handholding process get back competitive changesgary gillheeney president chief executive officer yeah really different based site care hopd know hospital setting process know kind like vac process got get back committee get back formulary take little bit longer process office little quicker get attention obviously clinician get process usually lot faster typically like see would like see know product actually reimbursed start slow side care know small order wait see reimbursement work understood know educate buying pattern start move back historically longer delay hopd also general delay people want see exactly reimbursement change fact know back reimbursement real particularly office follow close hospital cautious coming back testing reimbursementdrew ranieri morgan stanley analyst got great maybe licensing agreement discussed appreciate growthaccretive marginaccretive help u frame significant could advance wound care business give u sense kind like true inorganic number versus organic appreciating license gary also talked bit prepared remark new new product maybe help u factored guidance lookout incremental better mix thanks taking questionsdave francisco chief financial officer yeah drew incorporated guidance know done last several quarter kind moving away productspecific disclosure know incorporated guidance mentioned discussion ross know looking forward letting know progress going forward disclosing level detail even pure applied level broken give u drew give u know flexibility optionality product mix give u flexibility site care certainly expect contribute growth know drew ranieri morgan stanley analyst got new product lookout broadly portfolio thank yougary gillheeney president chief executive officer well mention two product launching surgery know expecting product contribute wound care surgery primarily surgical area larger piece pure applied technologyoperatoroperator signoff duration minutescall participantsgary gillheeney president chief executive officerdave francisco chief financial officerryan zimmerman btig analystross osborn cantor fitzgerald analystdrew ranieri morgan stanley analyst orgo analysis earnings call transcript article transcript conference call produced motley fool strive foolish best may error omission inaccuracy transcript article motley fool assume responsibility use content strongly encourage research including listening call reading company sec filing please see term condition additional detail including obligatory capitalized disclaimer liabilitythe motley fool position stock mentioned motley fool disclosure policy